低分子肝素在生殖领域的应用

doi:10.6040/j.issn.1671-7554.0.2024.0727

摘要/Abstract

摘要： 低分子肝素(low molecular weight heparin, LMWH)是临床上最常用的肝素类抗凝药,对母体及胎儿相对安全。目前LMWH在辅助生殖过程中广泛应用,在预防血栓,提高胚胎种植率,降低自然流产风险等方面均有临床研究报道,然而使用剂量及证据等级并不明确。本综述旨在总结LMWH在辅助生殖临床应用的相关研究,以期为LMWH在临床治疗的合理应用提供相关参考信息,并期待为LMWH在辅助生殖领域的临床及基础研究提供思路。

关键词: 低分子肝素, 辅助生殖技术, 体外受精, 反复种植失败, 复发性流产, 卵巢过度刺激, 多囊卵巢综合征

Abstract: Low molecular weight heparin(LMWH)is the most commonly used heparin anticoagulant, which is relatively safe for mother and fetus. At present, LMWH has been widely used in assisted reproduction, and clinical studies have reported its efficacy in preventing thrombosis, increasing embryo implantation rates, reducing the risk of spontaneous abortion, etc. However, the dosage and level of evidence are not clear. This review summarized the relevant studies on the clinical application of LMWH in assisted reproduction, in order to provide relevant reference information for the reasonable application of LMWH in clinic, and to provide ideas for the clinical and basic research of LMWH in the field of assisted reproduction.

Key words: Low molecular weight heparin, Assisted reproductive technology, In vitro fertilization, Recurrent implantation failure, Recurrent spontaneous abortion, Ovarian hyperstimulation syndrome, Polycystic ovary syndrome

中图分类号:

R339.2

万文静,高姗姗. 低分子肝素在生殖领域的应用[J]. 山东大学学报 (医学版), 2025, 63(6): 117-124.

WAN Wenjing, GAO Shanshan. Application of low molecular weight heparin in reproductive field[J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 117-124.

参考文献

[1] Glujovsky D, Quinteiro Retamar AM, Alvarez Sedo CR, et al. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology[J]. Cochrane Database Syst Rev, 2022, 5(5): CD002118. doi: 10.1002/14651858.CD002118.pub6
[2] Jacobson B, Rambiritch V, Paek D, et al. Safety and efficacy of enoxaparin in pregnancy: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(1): 27-40.
[3] Greer IA. Exploring the role of low-molecular-weight hepa-rins in pregnancy[J]. Semin Thromb Hemost, 2002, 28(Suppl 3): 25-31.
[4] 中华医学会妇产科学分会产科学组, 复发性流产诊治专家共识编写组. 复发性流产诊治专家共识(2022)[J]. 中华妇产科杂志, 2022, 57(9): 653-667. The Group of Obstetrics, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association, Expert consensus group for diagnosis and treatment of recurrent spontaneous abortion. Expert consensus on diagnosis and treatment of recurrent spontaneous abortion(2022)[J]. Chinese Journal of Obstetrics and Gynecology, 2022, 57(9): 653-667.
[5] The ESHRE Guideline Group on RPL, Atik RB, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss[J]. Hum Reprod Open, 2018, 2018(2): hoy004. doi: 10.1093/hropen/hoy004
[6] Toth B, Würfel W, Bohlmann M, et al. Recurrent miscarriage: diagnostic and therapeutic procedures. guideline of the DGGG, OEGGG and SGGG(S2k-level, AWMF registry number 015/050)[J]. Geburtshilfe Frauenheilkd, 2018, 78(4): 364-381.
[7] 中华医学会血液学分会血栓与止血学组. 易栓症诊断与防治中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(11): 881-888. Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis, prevention and treatment of thrombophilia(2021)[J]. Chinese Journal of Hematology, 2021, 42(11): 881-888.
[8] 张译爻, 王玉贤, 崔向荣. 复发性流产与遗传性易栓症的研究进展[J]. 中国临床研究, 2022, 35(10): 1449-1453. ZHANG Yiyao, WANG Yuxian, CUI Xiangrong. Research progress of recurrent abortion and hereditary thrombophilia[J]. Chinese Journal of Clinical Research, 2022, 35(10): 1449-1453.
[9] 国家妇幼健康研究会生殖免疫学专业委员会专家共识编写组. 复发性流产合并血栓前状态诊治中国专家共识[J]. 中华生殖与避孕杂志, 2021, 41(10): 861-875. Expert consensus writing group of Reproductive Immunology Committee of National Maternal and Child Health Research Association. Chinese expert consensus on the diagnosis and treatment of recurrent spontaneous abortion complicated with prethrombotic state [J]. Chinese Journal of Reproduction and Contraception, 2021, 41(10): 861-875.
[10] The ESHRE Guioleline Group on RPL, Atik RB, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022[J]. Hum Reprod Open, 2023, 2023(1): hoad002. doi:10.1093/hropen/hoad002
[11] Hamulyák EN, Scheres LJJ, Goddijn M, et al. Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence?[J]. J Thromb Haemost, 2021, 19(5): 1174-1185.
[12] Zullino S, Clemenza S, Mecacci F, et al. Low molecular weight heparins(LMWH)and implications along pregnancy: a focus on the placenta[J]. Reprod Sci, 2022, 29(5): 1414-1423.
[13] Hogwood J, Mulloy B, Lever R, et al. Pharmacology of heparin and related drugs: an update[J]. Pharmacol Rev, 2023, 75(2): 328-379.
[14] Xu GL, Hu XF, Han YM, et al. Clinical efficacy of low molecular heparin on unexplained recurrent spontaneous abortion[J]. Clin Lab, 2018, 64(6): 1037-1040.
[15] Shaaban OM, Abbas AM, Zahran KM, et al. Low-molecular-weight heparin for the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies: a randomized controlled trial[J]. Clin Appl Thromb Hemost, 2017, 23(6): 567-572.
[16] Cetin O, Karaman E, Cim N, et al. The impact of low molecular weight heparin on obstetric outcomes among unexplained recurrent miscarriages complicated with methylenetetrahydrofolate reductase gene polymorphism[J]. Ginekol Pol, 2017, 88(5): 260-265.
[17] Mohammad-Akbari A, Mohazzab A, Tavakoli M, et al. The effect of low-molecular-weight heparin on live birth rate of patients with unexplained early recurrent pregnancy loss: a two-arm randomized clinical trial[J]. J Res Med Sci, 2022, 27: 78. doi:10.4103/jrms.jrms_81_21
[18] Awolumate OJ, Kang A, Khokale R, et al. Role of low molecular weight heparin in the management of unexplained recurrent pregnancy loss: a review of literature[J]. Cureus, 2020, 12(10): e10956. doi:10.7759/cureus.10956
[19] Grandone E, Piazza G. Thrombophilia, inflammation, and recurrent pregnancy loss: a case-based review[J]. Semin Reprod Med, 2021, 39(1/2): 62-68.
[20] Working Group on Recurrent Implantation Failure ESHRE, Cimadomo D, de Los Santos MJ, et al. ESHRE good practice recommendations on recurrent implantation failure[J]. Hum Reprod Open, 2023, 2023(3): hoad023. doi:10.1093/hropen/hoad023
[21] 中国医师协会生殖医学专业委员会, 中国女医师协会生殖医学专业委员会. 反复种植失败临床诊治中国专家共识[J]. 中华医学杂志, 2023, 103(2): 89-100. Chinese Association of Reproductive Medicine Professional Committee of Reproductive Medicine, China Medical Women’s Association. Expert consensus on diagnosis and treatment of recurrent implantation failure[J]. National Medical Journal of China, 2023, 103(2): 89-100.
[22] Sung N, Khan SA, Yiu ME, et al. Reproductive outcomes of women with recurrent pregnancy losses and repeated implantation failures are significantly improved with immunomodulatory treatment[J]. J Reprod Immunol, 2021, 148: 103369. doi:10.1016/j.jri.2021.103369
[23] Chen JS, Bie J, Jiang FJ, et al. Low-molecular-weight heparin in thrombophilic women receiving in vitro fertilization/intracytoplasmic sperm injection: a meta-analysis[J]. Acta Obstet Gynecol Scand, 2023, 102(11): 1431-1439.
[24] Chamley LW, Duncalf AM, Mitchell MD, et al. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death[J]. Lancet, 1998, 352(9133): 1037-1038.
[25] Grandone E, Colaizzo D, Bue AL, et al. Inherited thrombophilia and in vitro fertilization implantation failure[J]. Fertil Steril, 2001, 76(1): 201-202.
[26] Azem F, Many A, Ben Ami I, et al. Increased rates of thrombophilia in women with repeated IVF failures[J]. Hum Reprod, 2004, 19(2): 368-370.
[27] Leach RE, Kilburn B, Wang J, et al. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype[J]. Dev Biol, 2004, 266(2): 223-237.
[28] Spratte J, Schönborn M, Treder N, et al. Heparin modulates chemokines in human endometrial stromal cells by interaction with tumor necrosis factor α and thrombin[J]. Fertil Steril, 2015, 103(5): 1363-1369.
[29] Shomer E, Katzenell S, Zipori Y, et al. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function[J]. Thromb Res, 2016, 137: 141-147. doi:10.1016/j.thromres.2015.11.026
[30] Fluhr H, Carli S, Deperschmidt M, et al. Differential effects of human chorionic gonadotropin and decidualization on insulin-like growth factors-I and -II in human endometrial stromal cells[J]. Fertil Steril, 2008, 90(4 Suppl): 1384-1389. doi: 10.1016/j.fertnstert.2007.07.1357
[31] Armant DR, Kilburn BA, Petkova A, et al. Human trophoblast survival at low oxygen concentrations requires metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor[J]. Development, 2006, 133(4): 751-759.
[32] Urman B, Ata B, Yakin K, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial[J]. Hum Reprod, 2009, 24(7): 1640-1647.
[33] Berker B, Taşkin S, Kahraman K, et al. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study[J]. Fertil Steril, 2011, 95(8): 2499-2502.
[34] Dason ES, Koshkina O, Chan C, et al. Diagnosis and management of polycystic ovarian syndrome[J]. CMAJ, 2024, 196(3): 85-94.
[35] Machin N, Ragni MV. Hormones and thrombosis: risk across the reproductive years and beyond[J]. Transl Res, 2020, 225: 9-19. doi:10.1016/j.trsl.2020.06.011
[36] Huang O, Ding HX, Wu DD, et al. A randomized, controlled clinical study of low-molecular-weight heparin improving pregnancy outcomes in PCOS women undergoing IVF: study protocol[J]. Trials, 2024, 25(1): 16. doi:10.1186/s13063-023-07877-x
[37] Sun Q, Yang Y, Peng XN, et al. Coagulation parameters predictive of polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 240: 36-40. doi:10.1016/j.ejogrb.2019.06.018
[38] Di Micco P, Russo V, Mastroiacovo D, et al. In vitro fertilization procedures with embryo transfer and their association with thrombophilia, thrombosis and early antithrombotic treatments[J]. J Blood Med, 2020, 11: 185-190. doi:10.2147/JBM.S248988
[39] Kasum M, Danoli c D, Oreškovi c S, et al. Thrombosis following ovarian hyperstimulation syndrome[J]. Gynecol Endocrinol, 2014, 30(11): 764-768.
[40] Jó zwik M. The mechanism of thromboembolism in the course of ovarian hyperstimulation syndrome[J]. Med Wieku Rozwoj, 2012, 16(4): 269-271.
[41] Várnagy A, Bódis J, Mánfai Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome[J]. Fertil Steril, 2010, 93(7): 2281-2284.
[42] Wang LC, Brown JR, Varki A, et al. Heparins anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins[J]. J Clin Invest, 2002, 110(1): 127-136.
[43] Niu ZH, Zhou MJ, Xia L, et al. Uterine cytokine profiles after low-molecular-weight heparin administration are associated with pregnancy outcomes of patients with repeated implantation failure[J]. Front Endocrinol, 2022, 13: 1008923. doi:10.3389/fendo.2022.1008923
[44] Zhang KM, Wang ES, Li Y, et al. Role of low-molecular-weight heparin in altering uterine artery blood flow in recurrent spontaneous abortion: a prospective study[J]. J Int Med Res, 2020, 48(8): 300060520945558. doi:10.1177/0300060520945558
[45] 土增荣, 王丽媛, 段瑞云, 等. 宫腔内灌注粒细胞集落刺激因子加注射低分子肝素钙在薄型子宫内膜反复种植失败不孕症中应用研究[J]. 中国药物与临床, 2020, 20(9): 1435-1438. TU Zengrong, WANG Liyuan, DUAN Ruiyun, et al. Intrauterine perfusion of granulocyte colony-stimulating factor and injection of low molecular weight heparin in patients with thin endometrium following repeated implantation failure: a clinical study[J]. Chinese Remedies & Clinics, 2020, 20(9): 1435-1438.
[46] 哈力克库兰. 低分子肝素与阿司匹林联合治疗高龄复发性流产的疗效研究[J]. 世界最新医学信息文摘, 2018, 18(5): 95,101.
[47] Beurskens DMH, Huckriede JP, Schrijver R, et al. The anticoagulant and nonanticoagulant properties of heparin[J]. Thromb Haemost, 2020, 120(10): 1371-1383.
[48] Hills FA, Abrahams VM, González-Timón B, et al. Heparin prevents programmed cell death in human tropho-blast[J]. Mol Hum Reprod, 2006, 12(4): 237-243.
[49] DIppolito S, Di Nicuolo F, Marana R, et al. Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression[J]. Fertil Steril, 2012, 98(4): 1028-1036.
[50] Lacey H, Haigh T, Westwood M, et al. Mesenchymally-derived insulin-like growth factor 1 provides a paracrine stimulus for trophoblast migration[J]. BMC Dev Biol, 2002, 2: 5. doi:10.1186/1471-213x-2-5
[51] Møller AV, Jørgensen SP, Chen JW, et al. Glycosamino-glycans increase levels of free and bioactive IGF-I in vitro[J]. Eur J Endocrinol, 2006, 155(2): 297-305.
[52] Constancia M, Hemberger M, Hughes J, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth[J]. Nature, 2002, 417(6892): 945-948.
[53] Lash GE, Otun HA, Innes BA, et al. Inhibition of trophoblast cell invasion by TGFB1, 2, and 3 is associated with a decrease in active proteases[J]. Biol Reprod, 2005, 73(2): 374-381.
[54] Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Low-molecular weight heparin induces in vitro trophoblast inva-siveness: role of matrix metalloproteinases and tissue inhibitors[J]. Placenta, 2007, 28(4): 298-304.
[55] Di Simone N, Di Nicuolo F, Castellani R, et al. Low-molecular-weight heparins induce decidual heparin-binding epidermal growth factor-like growth factor expression and promote survival of decidual cells undergoing apoptosis[J]. Fertil Steril, 2012, 97(1): 169-177.
[56] Li QP, Zhang Y, Zou L. The effect of low-molecular-weight heparin on immune balance of patients with repeated implantation failure during the implantation window[J]. Cell Mol Biol, 2023, 69(4): 112-115.
[57] Quenby S, Booth K, Hiller L, et al. Heparin for women with recurrent miscarriage and inherited thrombophilia(ALIFE2): an international open-label, randomised controlled trial[J]. Lancet, 2023, 402(10395): 54-61.
[58] 倪丽, 吴兆勇, 毛书辉, 等. 妊娠期低分子肝素使用的研究进展[J]. 中国现代医生, 2022, 60(7): 189-192. NI Li, WU Zhaoyong, MAO Shuhui, et al. Advances in research on the use of low molecular heparin during preg-nancy[J]. China Modern Doctor, 2022, 60(7): 189-192.
[59] 曾中虹, 杨一华. 不明原因反复胚胎种植失败和不明原因反复流产的病因学差异[J]. 生殖医学杂志, 2022, 31(7): 998-1003. ZENG Zhonghong, YANG Yihua. Etiological differences between unexplained recurrent implantation failure and unexplained recurrent spontaneous abortion[J]. Journal of Reproductive Medicine, 2022, 31(7): 998-1003.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed